A recent study reveals that individuals who come off popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop conventional diet and exercise plans.
Research printed in a prominent health publication shows that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People buying these medications must be cognizant of the danger of quick rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass in about 18 months.
Comparing Approaches
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Researchers point out that individuals who lose weight through diet and exercise usually experience a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts believe the mechanism of the jabs accounts for the accelerated regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making overeating far more likely."
A Lifelong Issue?
Health authorities suggest the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered ongoing.
This view is supported by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the jabs describe a powerful return of appetite.
"It felt as if something that goes on and you're instantly starving," described a patient.
This challenge is exacerbated if users have not established sustainable lifestyle or habit modifications during treatment.
Significant Use
Figures show that millions of adults in the UK have used these injections in the past year, with desire continuing to grow.
- Use is higher among females compared to males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic solution and long-term success likely depends on ongoing behavioural changes.